Ruchit Patel

Experience

Strategic Transactions

• Pfizer Inc. in its acquisition of Trillium Therapeutics Inc. for approximately $2.26 billion
• Acceleron Pharma on its approximately $11.5 billion million sale to Merck
• Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, in a billion-dollar worldwide co-development and co-commercialization agreement with Otsuka Pharmaceutical Co., Ltd. for four novel neurology drugs
• Takeda Pharmaceutical Company Limited in an exclusive collaboration and license agreement with JCR Pharmaceuticals Co., Ltd. to commercialize JR-141 for the treatment of Hunter syndrome
• Cove Hill Partners on the sale of LiveAuctioneers to Auction Technology Group plc for approximately $500 million 
• Baring Private Equity Asia on the sale of the global surgical business of Lumenis LTD. to Boston Scientific
• Google before the Competition Commission of India in its acquisition of an interest in Reliance Jio Platforms valued at $4.5 billion
• Wright Medical Group N.V. on its agreement to be acquired by Stryker Corp. in a transaction with a total enterprise value of approximately $5.4 billion
• Medical Properties Trust on its deal to acquire the real estate of 30 acute care hospital facilities in the United Kingdom for approximately $2 billion
• Baring Private Equity Asia in its $381 million acquisition of NIIT Technologies Limited (public to private)
• Milacron Holdings Corp. in the antitrust aspects of its pending $2 billion cash and stock merger with Hillenbrand, Inc.
• Wieland-Werke AG in its $1.2 billion acquisition of Global Brass and Copper Holdings, Inc.
• Avista on the antitrust aspects of the sale of Trimb Healthcare to Karo Pharma, cleared subject to divestitures
• Medtronic on its US$1.64 billion acquisition of Mazor Robotics Ltd
• Medtronic on the CMA review of its preferred partnership with Animas Corporation
• Blue Coat on the European aspects of its sale to Symantec valued at over US$4 billion
• Pfizer on the sale of its Hospira Infusion Business to ICU Medical, valued at US$1 billion
• Pfizer on its nearly US$14 billion acquisition of Medivation, Inc.
• Baring Private Equity Asia on its US$1.8 billion sale, alongside the Shanghai-based Bright Food Group, of British breakfast cereal brand Weetabix to U.S.-based cereal company, Post Holdings
• Medtronic in relation to the European aspects of an acquisition in the medical technology sector valued at over US$1 billion
• Medtronic on EC and ROW aspects of Medtronic’s US$43 billion acquisition of Covidien. Secured approvals from 13 jurisdictions and coordinated a single remedy globally
• Biomet, the divestiture buyer, on J&J’s US$21.3 billion acquisition of Synthes
• Merck on its animal health joint venture with Sanofi-Aventis (ultimately abandoned). Awarded GCR “Deal of the Year” in 2011 in recognition of its size and complexity
• Abbott on its US$4.5 billion acquisition of Solvay’s pharmaceuticals and diagnostics business, which was conditionally cleared at Phase

Private Equity Transactions

• Vista Equity Partners in their investment, along with TA Associates Management, in Aptean
• New Mountain Capital in acquiring ACETO Corporation’s chemicals business assets
• APG Asset Management on its €450 million joint venture with the US-based Hines Group in Cherrywood, a new home, school and leisure scheme, advising APG in relation to all antitrust aspects of the transaction, including securing clearance from the European Commission
• Bain Capital on its US$18 billion acquisition of Toshiba Memory Corporation from Toshiba Corporation, by way of a Bain Capital-led consortium including Apple, Seagate Technology, Kingston Technology, Hoya, Dell Technologies and SK Hynix
• Oakley Capital on the acquisition of TechInsights, a technology patent analysis business

Investigations

• Google with several multi-jurisdictional competition law investigations
• A multinational financial services organisation in the defense of allegations of collusion by the European Commission
• SK Hynix on settlement negotiations with the European Commission in DRAM
• IBM with a complaint to the European Commission in relation to “midrange” servers

Litigation & Counseling

• Metlac in defence of the Competition Commission’s decision to prohibit AkzoNobel’s acquisition of Metlac
• Boots plc in relation to Celesio’s appeal of the OFT’s decision in Boots/Alliance Unichem in the Competition Appeal Tribunal
• An intervener in relation to Ofgem’s decision to fine British Gas for exclusionary policy in relation to gas and electricity matter

Disclaimer

Ropes & Gray International LLP is a limited liability partnership registered in Delaware, United States of America and is a recognised body regulated by the Solicitors Regulation Authority (with registered number 521000).